Nerve damage is a common and painful side effect of chemotherapy. It can cause tingling, numbness, and weakness in the hands and feet, and sometimes forces people to stop treatment early. A new review pooled data from studies of 1,625 patients to see whether certain antioxidants could help prevent this problem.
The review looked at glutathione, N-acetylcysteine, and vitamin E compared with placebo. For mild nerve damage overall, none of these supplements made a clear difference. But for severe nerve damage, the picture was more promising. N-acetylcysteine was linked to about an 80% lower chance of severe nerve damage. Glutathione and vitamin E were each linked to roughly a 65% lower chance.
N-acetylcysteine ranked highest across the analyses. Still, the authors stress these findings are early and should not be overread. The results did not hold up when they looked only at the most rigorously designed trials, which weakens confidence in the findings.
The review did not report information on side effects, and it did not receive or disclose funding. Larger, carefully controlled trials are needed before these supplements could be recommended for preventing chemotherapy-related nerve damage. In the meantime, patients should talk with their care team before starting any supplement during treatment.
Common questions
Which antioxidants were linked to less severe nerve damage?
The review looked at glutathione, N-acetylcysteine and vitamin E, each compared with placebo. For severe (grade 3 or 4) nerve damage, N-acetylcysteine had an odds ratio of 0.19, glutathione 0.34 and vitamin E 0.33. N-acetylcysteine ranked highest across the analyses. These are early links, not proof, and the authors call for more rigorous trials.
Did these supplements reduce all nerve damage from chemo?
No. When the researchers looked at all grades of nerve damage combined, no intervention significantly reduced it compared with placebo. The possible benefit appeared only when they focused on severe grade 3 or 4 nerve damage. That split result is one reason to read the findings cautiously rather than as a clear win.
How strong is this evidence?
It is preliminary. The findings did not hold up in analyses limited to double-blind studies, which are designed to reduce bias. The review also did not report safety data such as side effects or dropouts. The authors say further rigorously conducted and adequately powered trials are needed before these results should change practice.
Should I take these supplements during chemotherapy?
This review does not answer that for any individual. It reports early associations, not confirmed benefits, and gives no safety information. Supplements can interact with cancer treatment, so talk with your oncology team before starting or stopping anything. Decisions about your care belong with your doctors, who know your full treatment plan.
